Alzheimer's disease (AD) is a neurodegenerative disorder that affects millions worldwide. In the absence of effective treatment options, early diagnosis is crucial for initiating management strategies to delay disease onset and slow down its progression. In this study, we propose Retformer, a novel transformer-based architecture for detecting AD using retinal imaging modalities, leveraging the power of transformers and explainable artificial intelligence. The Retformer model is trained on datasets of different modalities of retinal images from patients with AD and age-matched healthy controls, enabling it to learn complex patterns and relationships between image features and disease diagnosis. To provide insights into the decision-making process of our model, we employ the Gradient-weighted Class Activation Mapping algorithm to visualize the feature importance maps, highlighting the regions of the retinal images that contribute most significantly to the classification outcome. These findings are compared to existing clinical studies on detecting AD using retinal biomarkers, allowing us to identify the most important features for AD detection in each imaging modality. The Retformer model outperforms a variety of benchmark algorithms across different performance metrics by margins of up to 11\.

Alzheimer's Disease (AD) has become an increasingly critical global health concern, which necessitates effective monitoring solutions in smart health applications. However, the development of such solutions is significantly hindered by the scarcity of AD-specific activity datasets. To address this challenge, we propose SHADE-AD, a Large Language Model (LLM) framework for Synthesizing Human Activity Datasets Embedded with AD features. Leveraging both public datasets and our own collected data from 99 AD patients, SHADE-AD synthesizes human activity videos that specifically represent AD-related behaviors. By employing a three-stage training mechanism, it broadens the range of activities beyond those collected from limited deployment settings. We conducted comprehensive evaluations of the generated dataset, demonstrating significant improvements in downstream tasks such as Human Activity Recognition (HAR) detection, with enhancements of up to 79.69%. Detailed motion metrics between real and synthetic data show strong alignment, validating the realism and utility of the synthesized dataset. These results underscore SHADE-AD's potential to advance smart health applications by providing a cost-effective, privacy-preserving solution for AD monitoring.

Alzheimer's Disease (AD) is an irreversible neurodegenerative disease affecting 50 million people worldwide. Low-cost, accurate identification of key markers of AD is crucial for timely diagnosis and intervention. Language impairment is one of the earliest signs of cognitive decline, which can be used to discriminate AD patients from normal control individuals. Patient-interviewer dialogues may be used to detect such impairments, but they are often mixed with ambiguous, noisy, and irrelevant information, making the AD detection task difficult. Moreover, the limited availability of AD speech samples and variability in their speech styles pose significant challenges in developing robust speech-based AD detection models. To address these challenges, we propose DECT, a novel speech-based domain-specific approach leveraging large language models (LLMs) for fine-grained linguistic analysis and label-switched label-preserved data generation. Our study presents four novelties: We harness the summarizing capabilities of LLMs to identify and distill key Cognitive-Linguistic information from noisy speech transcripts, effectively filtering irrelevant information. We leverage the inherent linguistic knowledge of LLMs to extract linguistic markers from unstructured and heterogeneous audio transcripts. We exploit the compositional ability of LLMs to generate AD speech transcripts consisting of diverse linguistic patterns to overcome the speech data scarcity challenge and enhance the robustness of AD detection models. We use the augmented AD textual speech transcript dataset and a more fine-grained representation of AD textual speech transcript data to fine-tune the AD detection model. The results have shown that DECT demonstrates superior model performance with an 11% improvement in AD detection accuracy on the datasets from DementiaBank compared to the baselines.

Alzheimer's disease is a severe neurological brain disorder. It is not curable, but earlier detection can help improve symptoms in a great deal. The machine learning-based approaches are popular and well-motivated models for many medical image processing tasks such as computer-aided diagnosis. These techniques can vastly improve the process for accurate diagnosis of Alzheimer's disease. In this paper, we investigate the performance of these techniques for Alzheimer's disease detection and classification using brain MRI and PET images from the OASIS database. The proposed system takes advantage of the powerful artificial neural network and support vector machines as classifiers, as well as principal component analysis as a feature extraction technique. The results indicate that the combined scheme achieves good accuracy and offers a significant advantage over the other approaches.

With the rise of Large Language Models (LLMs), notably characterized by GPT frameworks, there emerges a catalyst for novel healthcare applications. Earlier iterations of chatbot caregivers, though existent, have yet to achieve a dimension of human-like authenticity. This paper unveils `MemoryCompanion' a pioneering digital health solution explicitly tailored for Alzheimer's disease (AD) patients and their caregivers. Drawing upon the nuances of GPT technology and prompt engineering, MemoryCompanion manifests a personalized caregiving paradigm, fostering interactions via voice-cloning and talking-face mechanisms that resonate with the familiarity of known companions. Using advanced prompt-engineering, the system intricately adapts to each patient's distinct profile, curating its content and communication style accordingly. This approach strives to counteract prevalent issues of social isolation and loneliness frequently observed in AD demographics. Our methodology, grounded in its innovative design, addresses both the caregiving and technological challenges intrinsic to this domain.

Early prediction of Alzheimer's disease (AD) is crucial for timely intervention and treatment. This study aims to use machine learning approaches to analyze longitudinal electronic health records (EHRs) of patients with AD and identify signs and symptoms that can predict AD onset earlier. We used a case-control design with longitudinal EHRs from the U.S. Department of Veterans Affairs Veterans Health Administration (VHA) from 2004 to 2021. Cases were VHA patients with AD diagnosed after 1/1/2016 based on ICD-10-CM codes, matched 1:9 with controls by age, sex and clinical utilization with replacement. We used a panel of AD-related keywords and their occurrences over time in a patient's longitudinal EHRs as predictors for AD prediction with four machine learning models. We performed subgroup analyses by age, sex, and race/ethnicity, and validated the model in a hold-out and "unseen" VHA stations group. Model discrimination, calibration, and other relevant metrics were reported for predictions up to ten years before ICD-based diagnosis. The study population included 16,701 cases and 39,097 matched controls. The average number of AD-related keywords (e.g., "concentration", "speaking") per year increased rapidly for cases as diagnosis approached, from around 10 to over 40, while remaining flat at 10 for controls. The best model achieved high discriminative accuracy (ROCAUC 0.997) for predictions using data from at least ten years before ICD-based diagnoses. The model was well-calibrated (Hosmer-Lemeshow goodness-of-fit p-value = 0.99) and consistent across subgroups of age, sex and race/ethnicity, except for patients younger than 65 (ROCAUC 0.746). Machine learning models using AD-related keywords identified from EHR notes can predict future AD diagnoses, suggesting its potential use for identifying AD risk using EHR notes, offering an affordable way for early screening on large population.

Alzheimer's Disease (AD) causes a continuous decline in memory, thinking, and judgment. Traditional diagnoses are usually based on clinical experience, which is limited by some realistic factors. In this paper, we focus on exploiting deep learning techniques to diagnose AD based on eye-tracking behaviors. Visual attention, as typical eye-tracking behavior, is of great clinical value to detect cognitive abnormalities in AD patients. To better analyze the differences in visual attention between AD patients and normals, we first conduct a 3D comprehensive visual task on a non-invasive eye-tracking system to collect visual attention heatmaps. We then propose a multi-layered comparison convolution neural network (MC-CNN) to distinguish the visual attention differences between AD patients and normals. In MC-CNN, the multi-layered representations of heatmaps are obtained by hierarchical convolution to better encode eye-movement behaviors, which are further integrated into a distance vector to benefit the comprehensive visual task. Extensive experimental results on the collected dataset demonstrate that MC-CNN achieves consistent validity in classifying AD patients and normals with eye-tracking data.

Alzheimer's disease (AD) constitutes a neurodegenerative disease with serious consequences to peoples' everyday lives, if it is not diagnosed early since there is no available cure. Alzheimer's is the most common cause of dementia, which constitutes a general term for loss of memory. Due to the fact that dementia affects speech, existing research initiatives focus on detecting dementia from spontaneous speech. However, little work has been done regarding the conversion of speech data to Log-Mel spectrograms and Mel-frequency cepstral coefficients (MFCCs) and the usage of pretrained models. Concurrently, little work has been done in terms of both the usage of transformer networks and the way the two modalities, i.e., speech and transcripts, are combined in a single neural network. To address these limitations, first we represent speech signal as an image and employ several pretrained models, with Vision Transformer (ViT) achieving the highest evaluation results. Secondly, we propose multimodal models. More specifically, our introduced models include Gated Multimodal Unit in order to control the influence of each modality towards the final classification and crossmodal attention so as to capture in an effective way the relationships between the two modalities. Extensive experiments conducted on the ADReSS Challenge dataset demonstrate the effectiveness of the proposed models and their superiority over state-of-the-art approaches.

As the aging of society continues to accelerate, Alzheimer's Disease (AD) has received more and more attention from not only medical but also other fields, such as computer science, over the past decade. Since speech is considered one of the effective ways to diagnose cognitive decline, AD detection from speech has emerged as a hot topic. Nevertheless, such approaches fail to tackle several key issues: 1) AD is a complex neurocognitive disorder which means it is inappropriate to conduct AD detection using utterance information alone while ignoring dialogue information; 2) Utterances of AD patients contain many disfluencies that affect speech recognition yet are helpful to diagnosis; 3) AD patients tend to speak less, causing dialogue breakdown as the disease progresses. This fact leads to a small number of utterances, which may cause detection bias. Therefore, in this paper, we propose a novel AD detection architecture consisting of two major modules: an ensemble AD detector and a proactive listener. This architecture can be embedded in the dialogue system of conversational robots for healthcare.

Researchers from the University of Tsukuba and IBM Research find that automatic analysis of patients' drawings can help differentiate between Alzheimer's disease and dementia with Lewy bodies Tsukuba, Japan--The two most common neurodegenerative dementias are Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). There is often an overlap of symptoms across these two diseases, which can make diagnoses difficult. Although biomarkers in cerebrospinal fluid sampling and neuroimaging are the most well-validated diagnostic biomarkers, they can be invasive, time-consuming, and expensive. Researchers in Japan have discovered that the characteristics of patients' drawing process can discriminate between patients with AD and DLB, offering a cheap, non-invasive, and quick screening tool. Recently, an analysis of drawing tests has been shown to be useful for the identification of AD as well as Parkinson's disease, another form of Lewy body spectrum disorders.